ArticleACS omega2026
Rapid Profiling, Fingerprinting, and Speciation of Poloxamer 188 in Biotherapeutic Drug Production Using Comprehensive Liquid Chromatography-Charge Reduction Mass Spectrometry Analysis.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Poloxamer 188 (P188) is an alternative surfactant to polysorbates in biologic formulations, stabilizing biotherapeutic drugs in solution. By mitigating the inherent risk of polysorbate 20/80 (PS 20/80) degradation by host cell proteins, P188 ensured product integrity. In cell culture, it is used to minimize bubble formation and reduce shear stress. However, P188's susceptibility to chemical degradation necessitates vigilant monitoring during production, formulation, and storage to ensure biotherapeutic quality and patient safety. The complex composition of P188 poses a significant analytical challenge for its characterization and quantification in the pharmaceutical industry. In this work, we demonstrate two liquid chromatography (LC) methods that can be coupled with either a mass spectrometer (MS) for characterization and measurement of intact P188 and its degradants or a charged aerosol detector (CAD) for quantitative analysis. First, a reversed-phase liquid chromatography (RP-LC) method was developed for the characterization of P188 raw material in solution. Second, a strong anion exchange liquid chromatography (SAX-LC) method was developed for the direct measurement of the poloxamer in biotherapeutic drug products. After online separation via the LC methods mentioned above, we utilize charge reduction mass spectrometry and two-dimensional ion density mapping visualization for rapid profiling, fingerprinting, and speciation of this polymer excipient. This approach offers a streamlined ion map for comprehensive identification of P188 species and their mass distribution in detail, including poloxamers, poly-(ethylene oxides), and poly-(propylene oxides). The graphical representation of the data in two dimensions facilitates the visualization of these characteristics, enabling a prompt diagnosis of the purity and stability of P188. Consequently, both drug substances and drug products formulated with P188 can be directly analyzed, preserving high-integrity sample information. Simplified workflow and computer-assisted data processing also help increase the throughput.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.